GridAI Technologies (GRDX)
Orchestrates energy resources for AI data centers while retaining a legacy gastrointestinal drug program.
Something off on this page? Send us feedback.
Develops software to orchestrate storage, generation and grid connections for large data centers, with planned base-platform and performance fees. Its core platform remains pre-commercial alongside a legacy clinical-stage program for exocrine pancreatic insufficiency.
Develops an energy-orchestration platform coordinating battery storage, on-site generation and grid connections at campuses. The planned model combines base fees for visibility and orchestration with performance fees tied to power-cost optimization. Legacy DLS and ALICE Home Energy Management Systems remain supported but generate very little revenue.
Targets data-center developers, hyperscalers and energy-infrastructure developers in North America and Australia, following earlier trials in Australia that generated little commercial revenue. The platform was still under development and had not been commercially deployed. Integration depends on third-party batteries, control systems and energy-market infrastructure.
Retains Adrulipase in the GI Segment, a development-stage recombinant lipase for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. It completed clinical trials, while its pilot monotherapy study missed the primary efficacy endpoint. Execution depends on executives, consultants, contractors and subsidiary personnel because the registrant reported no employees.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.4M · Total debt $1.8M · Total assets $41.4M · Shareholders' equity $18.3M
- Revenue
- $85.9K
- Operating income
- −$3.0M
- Net income
- −$12.8M
No dividends on record.
| Institutions14 holders · as of Mar 31, 2026 | 4.89% | 348.6K shares | |
| Insiders7 holders · as of Jul 8, 2026 | 11.09% | 791.0K shares | |
| Otherremainder | 84.02% | 5.99M shares |
7.13M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (7.13M in the company's Sep 3, 2026 report, 3.36M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Jason David SawyerInsiderdirector, officer: Chief Executive Officer | 7.57% | 540,000 | 13Dfiled Jul 8, 2026 ↗ |
Renaissance Technologies LLCInstitution | 2.58% | 183,800 | 13Fas of Mar 31, 2026 |
Anna SkowronInsiderofficer: Interim CFO | 0.91% | 65,000 | Form 4filed Dec 29, 2025 ↗ |
Edward BorkowskiInsiderdirector | 0.84% | 60,248 | Form 4filed Jan 8, 2026 ↗ |
Federation Des Caisses Desjardins du QuebecInstitution | 0.67% | 47,800 | 13Fas of Mar 31, 2026 |
| See all 24 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
No open-market trades in the last 12 months.
- GE Vernova
Data-center power and grid orchestration at enterprise scale.
- Fluence Energy
Battery-storage software and controls for grid-connected assets.
- Stem
Software and edge controls for solar-plus-storage operations.
- Itron
Utility DERMS and virtual-power-plant control for flexible assets.
- Generac
Distributed batteries, generators, and energy controls for power users.
- AbbVie
Marketed pancreatic-enzyme therapy in the legacy EPI indication.
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GridAI Technologies | $3.62 | +2.99% | $11.6M | — | — | 72.5 | — |
| GE Vernova | $923.90 | +0.22% | $245.54B | 26.5 | 44.1 | 5.9 | +21.9% |
| Fluence Energy | $10.07 | −4.82% | $1.95B | — | — | 0.7 | +7.9% |
| Stem | $5.52 | +1.54% | $48.9M | — | — | 0.3 | −12.2% |
| Itron | $96.58 | +0.41% | $4.21B | 16.0 | 14.9 | 1.8 | −7.2% |
| Generac | $180.06 | −0.36% | $10.64B | 41.6 | 17.9 | 2.4 | +10.6% |
| AbbVie | $261.51 | −0.08% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Median | 34.1 | 17.6 | 2.1 | +9.0% |